Dosimetry of cytostatics in hyperthermic regional isolated perfusion
- PMID: 3967166
- DOI: 10.1002/1097-0142(19850215)55:4<698::aid-cncr2820550404>3.0.co;2-2
Dosimetry of cytostatics in hyperthermic regional isolated perfusion
Abstract
During the period from February to October 1983, 21 patients with malignant melanoma of the extremities were treated by hyperthermic regional isolated perfusion with L-phenylalanine mustard (melphalan). The melphalan dose for each patient was determined by the tissue volume of the perfused region, using a dose of 10 mg/l perfused tissue. Despite an average increase of melphalan dosage of 18% above the maximum for iliac perfusions recommended in the literature, no increase in toxic tissue reactions was observed after hyperthermic iliac perfusions. The same dose of 10 mg/l perfused tissue was used in hyperthermic axillary perfusions, resulting in an average decrease of melphalan dosage of 14% below the minimum recommended in the literature. By applying a constant dose per unit tissue volume, a standardization of treatment is achieved. This excludes variations like body weight, age, type of complexion, and hair color, which so far have determined dosimetry.
Similar articles
-
[Regional hyperthermic perfusion with cytostatic agents in malignant melanoma of the extremities (author's transl)].Dtsch Med Wochenschr. 1981 Nov 27;106(48):1612-5. doi: 10.1055/s-2008-1070564. Dtsch Med Wochenschr. 1981. PMID: 7308000 German.
-
Hyperthermic regional perfusion with melphalan and a combination of melphalan and actinomycin D in the treatment of locally metastasized malignant melanomas of the extremities.J Surg Oncol. 1982 May;20(1):9-13. doi: 10.1002/jso.2930200103. J Surg Oncol. 1982. PMID: 7078190
-
Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions.Eur J Cancer Clin Oncol. 1982 Oct;18(10):905-10. doi: 10.1016/0277-5379(82)90235-8. Eur J Cancer Clin Oncol. 1982. PMID: 6891640
-
Isolated limb perfusion for melanoma.Surg Oncol Clin N Am. 2008 Oct;17(4):785-94, viii-ix. doi: 10.1016/j.soc.2008.04.005. Surg Oncol Clin N Am. 2008. PMID: 18722918 Review.
-
Hyperthermic adjuvant perfusion chemotherapy for Stage I malignant melanoma of the extremity with literature review.Cancer. 1983 Dec 1;52(11):2033-9. doi: 10.1002/1097-0142(19831201)52:11<2033::aid-cncr2820521111>3.0.co;2-f. Cancer. 1983. PMID: 6354421 Review.
Cited by
-
Isolated regional perfusion in malignant melanoma of the extremities.World J Surg. 1987 Aug;11(4):527-33. doi: 10.1007/BF01655819. World J Surg. 1987. PMID: 3630197 No abstract available.
-
Drug dosage in isolated limb perfusion: evaluation of a limb volume model for extremity volume calculation.World J Surg Oncol. 2014 Apr 1;12:81. doi: 10.1186/1477-7819-12-81. World J Surg Oncol. 2014. PMID: 24684972 Free PMC article.
-
The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.Br J Cancer. 1992 Jul;66(1):159-66. doi: 10.1038/bjc.1992.235. Br J Cancer. 1992. PMID: 1637666 Free PMC article.
-
Leakage measurement during selective limb perfusion using a gamma probe.Eur J Nucl Med. 1996 May;23(5):534-8. doi: 10.1007/BF00833388. Eur J Nucl Med. 1996. PMID: 8698058
-
Controversies concerning adjuvant regional isolated perfusion for stage I melanoma of the extremities.World J Surg. 1992 Mar-Apr;16(2):241-5. doi: 10.1007/BF02071527. World J Surg. 1992. PMID: 1561805
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical